COLLEGIUM PHARMACEUTICAL, INC 8-K

What Happened
Collegium Pharmaceutical, Inc. announced its financial results for the quarterly period and fiscal year ended December 31, 2025 in a press release dated February 26, 2026. On the same day the company also released an earnings presentation. Both documents were furnished to the SEC as Exhibits to an 8-K (filed Feb 26, 2026) signed by Colleen Tupper, Executive Vice President and Chief Financial Officer.

Key Details

• Press release with Q4 and FY2025 results issued February 26, 2026 and furnished as Exhibit 99.1.
• Earnings presentation released February 26, 2026 and furnished as Exhibit 99.2.
• The reported periods cover the quarterly period and the fiscal year ended December 31, 2025.
• The 8-K was furnished (not filed); signature on the report is by Colleen Tupper, EVP & CFO.

Why It Matters
This 8-K signals that Collegium has publicly reported its latest quarterly and full-year financial results and provided investor presentation materials — the primary sources for revenue, net income (or loss), cash flow, and any management commentary or guidance. Investors should read the attached press release and presentation to see the company’s reported earnings, revenue trends, liquidity and any forward-looking commentary, since those details can influence valuation and near-term stock movement.